G Protein Coupled Receptor Structure, Dynamics and Signaling

Information

  • Research Project
  • 10244897
  • ApplicationId
    10244897
  • Core Project Number
    R01NS028471
  • Full Project Number
    5R01NS028471-31
  • Serial Number
    028471
  • FOA Number
    PA-13-302
  • Sub Project Id
  • Project Start Date
    4/1/1990 - 34 years ago
  • Project End Date
    8/30/2022 - 2 years ago
  • Program Officer Name
    UMANAH, GEORGE KWABENA ESSIEN
  • Budget Start Date
    9/30/2021 - 3 years ago
  • Budget End Date
    8/30/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    31
  • Suffix
  • Award Notice Date
    9/23/2021 - 3 years ago
Organizations

G Protein Coupled Receptor Structure, Dynamics and Signaling

Project Summary G protein coupled receptors (GPCRs) are the largest family of receptors for hormones and neurotransmitters and therefore the largest group of targets for new therapeutics for a very broad spectrum of diseases including neuropsychiatric, cardiovascular, pulmonary and metabolic disorders, cancer and AIDS. While initially thought to signal exclusively though G proteins and function as two-state switches activated by hormones and neurotransmitters, research over the past 30 years has revealed that most GPCRs have complex and diverse signaling behaviors. A single GPCR can activate more than one G protein subtype as well as G protein independent signaling pathways such as arrestins. Many GPCRs exhibit basal, agonist independent activity. When considering one of the several possible downstream signaling pathways, a drug acting at the orthosteric binding pocket may exhibit one of four efficacy profiles. It may behave as an inverse agonist, suppressing basal activity, a full agonist, maximally activating the pathway, a partial agonist, promoting submaximal activity even at saturating concentrations, or a neutral antagonist, having no effect on basal signaling, but blocking the binding of other orthosteric ligands. The efficacy profile of a given ligand may differ for different signaling pathways such that a drug may behave as an agonist for a specific G protein subtype or arrestin while have no effect or inhibiting other signaling pathways. This pathway selective (or biased) signaling has become an important consideration for drug discovery, since one signaling pathway may produce therapeutic effects while another may lead to adverse effects. During the previous funding period we have applied crystallography and several biophysical methods to characterize the structure and dynamic character of the ?2 adrenergic receptor (?2AR). These studies provide evidence that the ?2AR is highly dynamic and conformationally complex. We hypothesize that this complexity is essential for their functional versatility, and believe that a more detailed understanding of this complex conformational landscape will provide mechanistic insights into targeted activation of a specific pathway with biased ligands. The goal of this proposal will be to understand the structural basis for GPCR signaling through multiple pathways using methods that will provide high-resolution structural constraints and characterize protein dynamics under more physiologic conditions.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R01
  • Administering IC
    NS
  • Application Type
    5
  • Direct Cost Amount
    347083
  • Indirect Cost Amount
    197837
  • Total Cost
    544920
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    853
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NINDS:544920\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    MIST
  • Study Section Name
    Molecular and Integrative Signal Transduction Study Section
  • Organization Name
    STANFORD UNIVERSITY
  • Organization Department
    BIOPHYSICS
  • Organization DUNS
    009214214
  • Organization City
    STANFORD
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    943052004
  • Organization District
    UNITED STATES